SMAC Mimetics Synergistically Cooperate with HDAC Inhibitors Enhancing TNF-α Autocrine Signaling

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Overexpression of inhibitor of apoptosis (IAP) proteins is linked to poor survival in ovarian cancer patients.
• Recurrent ovarian cancers exhibit resistance to apoptosis due to dysregulated IAP proteins.

Purpose of the Study:

• To identify synergistic drug combinations with the SMAC mimetic birinapant for recurrent ovarian cancer.
• To evaluate the efficacy and underlying mechanisms of SMAC mimetics combined with HDAC inhibitors.

Main Methods:

• High-throughput screening was employed to identify synergistic drug combinations with birinapant.
• In vitro and in vivo studies were conducted to assess the combination therapy's effects.
• Mechanistic studies investigated pathways including caspase activation, TNF-α upregulation, and NF-kB signaling.

Main Results:

• SMAC mimetics in combination with HDAC inhibitors demonstrated remarkable synergy against recurrent ovarian cancer.
• The combination therapy resulted in increased caspase activation and TNF-α upregulation.
• Convergent signaling pathways, including alternative NF-kB signaling, were activated by the combination.

Conclusions:

• The combination of SMAC mimetics and HDAC inhibitors offers a promising therapeutic strategy for recurrent ovarian cancer.
• These findings provide a strong rationale for integrating SMAC mimetics and HDAC inhibitors into clinical trials for ovarian cancer treatment.